Jens Geginat

Jens Geginat

Auto-generated profile, based on publicly available information

Jens Geginat

INGM, Istituto Nazionale Genetica Molecolare “Romeo ed Enrica Invernizzi” Milan Italy

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2004 in Annual Review of Immunology
Verified
Journal Article
Closed access
FSFederica Sallusto
Federica Sallusto
JGJens Geginat
Jens Geginat
ALAntonio Lanzavecchia
Antonio Lanzavecchia
The memory T cell pool functions as a dynamic repository of antigen-experienced T lymphocytes that accumulate over the lifetime of the individual. Recent studies indicate that memory T lymphocytes contain distinct populations of central memory (TCM) and effector memory (TEM) cells characterized by distinct homing capacity and effector function. This review addresses the heterogeneity of TCMand TEM, their differentiation stages, and the current models for their generation and maintenance in humans and mice.

7 May 2007 in Nature Immunology
Verified
Journal Article
Closed access
EREva Acosta Rodriguez
Eva Acosta Rodriguez
LRLaura Rivino
Laura Rivino
JGJens Geginat
Jens Geginat
DJDavid Jarrossay
David Jarrossay
MGMarco Gattorno
Marco Gattorno
GNGiorgio Napolitani
Giorgio Napolitani

1 October 2010 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
RSRobert Sabat
Robert Sabat
GGGerald Grütz
Gerald Grütz
KWKatarzyna Warszawska
Katarzyna Warszawska
SKStefan Kirsch
Stefan Kirsch
EWEllen Witte
Ellen Witte
JGJens Geginat
Jens Geginat

21 October 2019 in European Journal of Immunology
Verified
Journal Article
Open access
ACAndrea Cossarizza
Andrea Cossarizza
HCHyun-Dong Chang
Hyun-Dong Chang
ARAndreas Radbruch
Andreas Radbruch
AAAndreas Acs
Andreas Acs
DADieter Adam
Dieter Adam
AZArturo Zychlinsky
Arturo Zychlinsky
These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community. They provide the theory and key practical aspects of flow cytometry enabling immunologists to avoid the common errors that often undermine immunological data. Notably, there are comprehensive sections of all major immune cell types with helpful Tables detailing phenotypes in murine and human cells. The latest flow cytometry techniques and applications are also described, featuring examples of the data that can be generated and, importantly, how the data can be analysed. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid, all written and peer‐reviewed by leading experts in the field, making this an essential research companion.

29 April 2015 in Nature
Verified
Journal Article
Closed access
PDF file
NGNicola Gagliani
Nicola Gagliani
MVMaria Carolina Amezcua Vesely
Maria Carolina Amezcua Vesely
AIAndrea Iseppon
Andrea Iseppon
LBLeonie Brockmann
Leonie Brockmann
HXHao Xu
Hao Xu
RFRichard A. Flavell
Richard A. Flavell

1 November 2016 in Immunity
Verified
Journal Article
Open access
MSMarco De Simone
Marco De Simone
AAAlberto Arrigoni
Alberto Arrigoni
GRGrazisa Rossetti
Grazisa Rossetti
PGPaola Gruarin
Paola Gruarin
VRValeria Ranzani
Valeria Ranzani
MPMassimiliano Pagani
Massimiliano Pagani
Tumor-infiltrating regulatory T lymphocytes (Treg) can suppress effector T cells specific for tumor antigens. Deeper molecular definitions of tumor-infiltrating-lymphocytes could thus offer therapeutic opportunities. Transcriptomes of T helper 1 (Th1), Th17, and Treg cells infiltrating colorectal or non-small-cell lung cancers were compared to transcriptomes of the same subsets from normal tissues and validated at the single-cell level. We found that tumor-infiltrating Treg cells were highly suppressive, upregulated several immune-checkpoints, and expressed on the cell surfaces specific signature molecules such as interleukin-1 receptor 2 (IL1R2), programmed death (PD)-1 Ligand1, PD-1 Ligand2, and CCR8 chemokine, which were not previously described on Treg cells. Remarkably, high expression in whole-tumor samples of Treg cell signature genes, such as LAYN, MAGEH1, or CCR8, correlated with poor prognosis. Our findings provide insights into the molecular identity and functions of human tumor-infiltrating Treg cells and define potential targets for tumor immunotherapy.